BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38286872)

  • 41. Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease.
    van der Zee S; Vermeiren Y; Fransen E; Van Dam D; Aerts T; Gerritsen MJ; Spikman JM; van Laar T; De Deyn PP
    J Parkinsons Dis; 2018; 8(1):71-84. PubMed ID: 29480224
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neuroanatomical changes in early Parkinson's disease with mild cognitive impairment: a VBM study; the Parkinson's Disease Cognitive Impairment Study (PaCoS).
    Donzuso G; Monastero R; Cicero CE; Luca A; Mostile G; Giuliano L; Baschi R; Caccamo M; Gagliardo C; Palmucci S; Zappia M; Nicoletti A
    Neurol Sci; 2021 Sep; 42(9):3723-3731. PubMed ID: 33447925
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with
    Sheng ZH; Ma LZ; Liu JY; Ou YN; Zhao B; Ma YH; Tan L
    Front Aging Neurosci; 2022; 14():1061096. PubMed ID: 36589544
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reliability, validity, and diagnostic accuracy of Parkinson's Disease-Cognitive Rating Scale in Iranian patients with idiopathic Parkinson's disease.
    Mahmoudi Asl A; Mehdizadeh M; Kulisevsky J; Sabet A; Taghavi Azar Sharabiani P; Mehdizadeh H; Ashayeri H; Taghizadeh G
    Disabil Rehabil; 2022 May; 44(10):2091-2098. PubMed ID: 32924645
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantifying activities of daily living impairment in Parkinson's disease using the Functional Activities Questionnaire.
    Becker S; Pauly C; Lawton M; Hipp G; Bowring F; Sulzer P; Hu M; Krüger R; Gasser T; Liepelt-Scarfone I
    Neurol Sci; 2022 Feb; 43(2):1047-1054. PubMed ID: 34109514
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.
    Ng ASL; Tan YJ; Yong ACW; Saffari SE; Lu Z; Ng EY; Ng SYE; Chia NSY; Choi X; Heng D; Neo S; Xu Z; Keong NCH; Tay KY; Au WL; Tan LCS; Tan EK
    Mol Neurodegener; 2020 Jun; 15(1):33. PubMed ID: 32503574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An SBM-based machine learning model for identifying mild cognitive impairment in patients with Parkinson's disease.
    Zhang J; Li Y; Gao Y; Hu J; Huang B; Rong S; Chen J; Zhang Y; Wang L; Feng S; Wang L; Nie K
    J Neurol Sci; 2020 Nov; 418():117077. PubMed ID: 32798842
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.
    Schrag A; Siddiqui UF; Anastasiou Z; Weintraub D; Schott JM
    Lancet Neurol; 2017 Jan; 16(1):66-75. PubMed ID: 27866858
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Blood Lipid Biomarkers in Early Parkinson's Disease and Parkinson's Disease with Mild Cognitive Impairment.
    Deng X; Saffari SE; Ng SYE; Chia N; Tan JY; Choi X; Heng DL; Xu Z; Tay KY; Au WL; Liu N; Ng A; Tan EK; Tan LCS
    J Parkinsons Dis; 2022; 12(6):1937-1943. PubMed ID: 35723114
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A time-efficient screening tool for activities of daily living functions in Parkinson's disease dementia.
    Sulzer P; Liebig L; Csoti I; Graessel E; Wurster I; Berg D; Liepelt-Scarfone I
    J Clin Exp Neuropsychol; 2020 Oct; 42(8):867-879. PubMed ID: 33043797
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An assessment of Movement Disorder Society Task Force diagnostic criteria for mild cognitive impairment in Parkinson's disease.
    Uysal-Cantürk P; Hanağası HA; Bilgiç B; Gürvit H; Emre M
    Eur J Neurol; 2018 Jan; 25(1):148-153. PubMed ID: 28941002
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Andreasson U; Zetterberg H; Blennow K;
    JAMA Neurol; 2017 May; 74(5):557-566. PubMed ID: 28346578
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Blood NfL: A biomarker for disease severity and progression in Parkinson disease.
    Lin CH; Li CH; Yang KC; Lin FJ; Wu CC; Chieh JJ; Chiu MJ
    Neurology; 2019 Sep; 93(11):e1104-e1111. PubMed ID: 31420461
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of the serum microRNA-29 family with cognitive impairment in Parkinson's disease.
    Han L; Tang Y; Bai X; Liang X; Fan Y; Shen Y; Huang F; Wang J
    Aging (Albany NY); 2020 Jul; 12(13):13518-13528. PubMed ID: 32649312
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Six-item Clock-Drawing Scoring System: a rapid screening for cognitive impairment in Parkinson's disease.
    Lolekha P; Tangkanakul C; Saengchatri T; Kulkeartprasert P
    Psychogeriatrics; 2021 Jan; 21(1):24-31. PubMed ID: 32875700
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Measuring mild cognitive impairment in patients with Parkinson's disease.
    Marras C; Armstrong MJ; Meaney CA; Fox S; Rothberg B; Reginold W; Tang-Wai DF; Gill D; Eslinger PJ; Zadikoff C; Kennedy N; Marshall FJ; Mapstone M; Chou KL; Persad C; Litvan I; Mast BT; Gerstenecker AT; Weintraub S; Duff-Canning S
    Mov Disord; 2013 May; 28(5):626-33. PubMed ID: 23520128
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased plasma levels of phospholipid in Parkinson's disease with mild cognitive impairment.
    Li Z; Zhang J; Sun H
    J Clin Neurosci; 2015 Aug; 22(8):1268-71. PubMed ID: 26055959
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnosing mild cognitive impairment in Parkinson's disease: which tests perform best in the Italian population?
    Federico A; Trentin M; Zanette G; Mapelli D; Picelli A; Smania N; Tinazzi M; Tamburin S
    Neurol Sci; 2017 Aug; 38(8):1461-1468. PubMed ID: 28550344
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fist-Edge-Palm (FEP) test has a high sensitivity in differentiating dementia from normal cognition in Parkinson's disease.
    Liu Y; Qiu MY; Zhang YL; Zhang XJ; Truong D; Tan EK; Wu YC
    J Neurol Sci; 2021 Oct; 429():118060. PubMed ID: 34479167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.